GlassScriptPhysician profile
Lesley Reyes
NPI 1003691403
$2,765.56
in general payments reported to CMS, 2019-2025
23 companies · $797 in 2025
The $797 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $223 · 2024: $1,745 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $584.31 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $412.95 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $382.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $265.31 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $144.10 | 2023-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $140.27 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $105.11 | 2023-2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.76 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $96.35 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.63 | 2023-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $70.65 | 2024-2025 | Nexletol |
| Glaxosmithkline, LLC. | $63.06 | 2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $55.04 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.94 | 2024-2025 | Caplyta |
| Shield Therapeutics INC | $34.28 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.06 | 2025 | |
| Ascensia Diabetes Care US INC. | $24.57 | 2025 | |
| Boston Scientific Corporation | $24.50 | 2025 | Ams 700 |
| Ardelyx, INC. | $24.22 | 2024 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $18.71 | 2024 | Quviviq |
| Alkermes, INC. | $16.53 | 2024 | Vivitrol |
| Astellas Pharma US INC | $16.35 | 2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $14.74 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.